OncoMatch/Clinical Trials/NCT05512481

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

Is NCT05512481 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Camrelizumab for melanoma.

Phase 2RecruitingPeking University Cancer Hospital & InstituteNCT05512481Data as of May 2026

Treatment: Camrelizumab — Neoadjuvant therapy is feasible in stage Ⅱ-Ⅲ melanoma, Carrelizumab combined with apatinib and temozolomide has synergistic antitumor effects and may improve pathological response.

Check if I qualify

Extracted eligibility criteria

Cancer type

Melanoma

Disease stage

Required: Stage Ⅱ, Ⅲ

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: chemotherapy

Patients who have or are currently undergoing additional chemotherapy

Cannot have received: radiation therapy

Patients who have or are currently undergoing additional...radiation therapy

Cannot have received: targeted therapy

Patients who have or are currently undergoing additional...targeted therapy

Cannot have received: immunotherapy

Patients who have or are currently undergoing additional...immunotherapy

Lab requirements

Blood counts

Kidney function

Liver function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify